US FDA Revises Drug Facility Inspection Framework to Strengthen Regulatory Oversight

The United States Food and Drug Administration (US FDA) has introduced an updated framework for evaluating and inspecting pharmaceutical manufacturing facilities, aiming to improve regulatory coordination, operational efficiency and compliance monitoring. The revised framework, known as Concept of Operations 2.0 (ConOps 2.0), replaces the earlier version introduced in June 2017.

The updated framework strengthens collaboration between the FDA's Center for Drug Evaluation and Research (CDER) and the Office of Inspections and Investigations (OII). It seeks to streamline facility assessments by integrating inspection activities with drug application reviews, thereby reducing duplication and improving consistency in regulatory decisions.

A significant development is the formal inclusion of Remote Regulatory Assessments (RRAs), allowing the agency to evaluate manufacturing facilities through additional methods beyond conventional on-site inspections. The framework also recognises inspection reports from international regulatory authorities operating under Mutual Recognition Agreements (MRAs), enabling the FDA to incorporate findings from trusted overseas inspection partners.

ConOps 2.0 places greater emphasis on risk-based inspections, improved information sharing and clearly defined responsibilities among regulatory teams. It also establishes internal timelines for preapproval, postapproval, surveillance and for-cause inspections, supporting more efficient regulatory procedures.

For pharmaceutical manufacturers, the revised approach reinforces the need to maintain accurate documentation, reliable manufacturing records and robust data integrity practices. Contract manufacturing organisations and contract development and manufacturing organisations must also remain prepared for regulatory assessments.

The revised framework reflects the FDA's efforts to modernise pharmaceutical oversight while maintaining stringent Good Manufacturing Practice (GMP) standards and ensuring consistent evaluation of drug manufacturing facilities.

11-11-2026